190 related articles for article (PubMed ID: 37033919)
1. Non-viral
Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
[TBL] [Abstract][Full Text] [Related]
2. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies.
Zhang X; Wang T; Zhu X; Lu Y; Li M; Huang Z; Han D; Zhang L; Wu Y; Li L; Klawonn F; Stripecke R
Front Immunol; 2023; 14():1103695. PubMed ID: 36817460
[TBL] [Abstract][Full Text] [Related]
3. CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.
Slabik C; Kalbarczyk M; Danisch S; Zeidler R; Klawonn F; Volk V; Krönke N; Feuerhake F; Ferreira de Figueiredo C; Blasczyk R; Olbrich H; Theobald SJ; Schneider A; Ganser A; von Kaisenberg C; Lienenklaus S; Bleich A; Hammerschmidt W; Stripecke R
Mol Ther Oncolytics; 2020 Sep; 18():504-524. PubMed ID: 32953984
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Feng M; Luo C; Wan X; Pan C; Tang J; Xue F; Yin M; Lu D; Xia Q; Li B; Chen J
Cell Transplant; 2021; 30():963689721996649. PubMed ID: 33631963
[TBL] [Abstract][Full Text] [Related]
5. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
7. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Yu M; Zhang Q; Xu S; Yin T; Li F
Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
[TBL] [Abstract][Full Text] [Related]
9. Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV
Hernández DM; Valderrama S; Gualtero S; Hernández C; López M; Herrera MV; Solano J; Fiorentino S; Quijano S
Front Immunol; 2018; 9():2291. PubMed ID: 30337929
[TBL] [Abstract][Full Text] [Related]
10. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
Smith NA; Coleman CB; Gewurz BE; Rochford R
J Virol; 2020 May; 94(11):. PubMed ID: 32238579
[TBL] [Abstract][Full Text] [Related]
11. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
12. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
Chatterjee B; Deng Y; Holler A; Nunez N; Azzi T; Vanoaica LD; Müller A; Zdimerova H; Antsiferova O; Zbinden A; Capaul R; Dreyer JH; Nadal D; Becher B; Robinson MD; Stauss H; Münz C
PLoS Pathog; 2019 May; 15(5):e1007748. PubMed ID: 31145756
[TBL] [Abstract][Full Text] [Related]
14. PD-1 Blockade Aggravates Epstein-Barr Virus
Volk V; Theobald SJ; Danisch S; Khailaie S; Kalbarczyk M; Schneider A; Bialek-Waldmann J; Krönke N; Deng Y; Eiz-Vesper B; Dragon AC; von Kaisenberg C; Lienenklaus S; Bleich A; Keck J; Meyer-Hermann M; Klawonn F; Hammerschmidt W; Delecluse HJ; Münz C; Feuerhake F; Stripecke R
Front Oncol; 2020; 10():614876. PubMed ID: 33511078
[TBL] [Abstract][Full Text] [Related]
15. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
Ma SD; Xu X; Jones R; Delecluse HJ; Zumwalde NA; Sharma A; Gumperz JE; Kenney SC
PLoS Pathog; 2016 May; 12(5):e1005642. PubMed ID: 27186886
[TBL] [Abstract][Full Text] [Related]
16. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
17. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
[TBL] [Abstract][Full Text] [Related]
19. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
[TBL] [Abstract][Full Text] [Related]
20. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S; Ando M; Ando J; Ishii M; Yamaguchi T; Yamazaki S; Toyota T; Ohara K; Ohtaka M; Nakanishi M; Shin C; Ota Y; Nakashima K; Ohshima K; Imai C; Nakazawa Y; Nakauchi H; Komatsu N
Mol Ther; 2022 Feb; 30(2):534-549. PubMed ID: 34628050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]